Rare Disease Clinical Outcome Assessment Consortium (U01 Clinical Trial Not Allowed)

A rare disease is defined by the Orphan Drug Act as a disease that affects less than 200,000 people in the US.

As described in FDA draft Guidance, "Rare Diseases:
Common Issues in Drug Development Guidance for Industry" (https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm45848

credit:


5. pdf ), fit-for-purpose clinical endpoints for many rare diseases are not available.

Selection or development of clinical outcome assessments for use to support efficacy of a treatment in a rare disease can be challenging due to the small sample size of possible participants for participation in instrument development and clinical trials and heterogeneity of the target patient population (e.g., phenotypic or genotypic variations, age, clinical manifestations, variations in patient experience, and rate of disease progression).

However, many rare diseases share similar clinical characteristics such as decline in cognition and physical function, which offers an opportunity to explore clinical outcome assessments that may cover a spectrum of rare diseases.

This cooperative agreement will provide funding to establish a rare disease consortium focusing on clinical outcome assessments appropriate for use in drug development to demonstrate clinical benefit.

Many rare diseases include neurodegenerative decline resulting in loss of ability to perform daily activities.

Therefore, domains of interest include, but are not limited to, cognition, adaptive behavior, physical function (e.g., fine motor function, ambulation, speech, swallowing) and assessments of patients' ability to perform activities of daily living.

Special considerations that should be addressed include the fact that many rare diseases affect children as well as adults and trials are often multiregional, which necessitates attention to cross-cultural considerations.

The final outcome would be the creation of a common resource describing publicly available fit-for-purpose clinical outcome assessments as well as accompanying information, such as the populations for use and the strengths and limitations of each tool.

Work in the pre-competitive setting of a consortium where data is shared can enhance the development of this resource and, thus would help to address unmet measurement needs in rare disease drug development.

Related Programs

Food and Drug Administration_Research

Department of Health and Human Services


Agency: Department of Health and Human Services

Office: Food and Drug Administration

Estimated Funding: $300,000


Relevant Nonprofit Program Categories





Obtain Full Opportunity Text:
http://www.grants.gov

Additional Information of Eligibility:
This is a "Notice of Intent" of a single source task agreement award to the University of Minnesota, Duluth, MN under the Great Lakes Cooperative Ecosystem Studies Unit (CESU).

The principle investigator (PI) has a unique capability that is important to the development and dissemination of aquatic invasive species (AIS) public education programming on Minnesota's North Shore.

The PI is currently the only aquatic invasive education specialist working full time in the North Shore area and has unique capabilities in terms of research, design, publication, and dissemination of scientifically-accurate AIS materials.

The PI is also the area coordinator for the "Stop Aquatic Hitchhikers!" public information campaign, which is currently the leading multi-agency effort in AIS education on Lake Superior.



Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-19-029.html

Contact:


Agency Email Description:
shashi.malhotra@fda.hhs.gov

Agency Email:


Date Posted:
2019-06-04

Application Due Date:


Archive Date:
2019-08-28



Social Entrepreneurship
Spotlight



How Being a Social Enterprise Apprentice Changed Life of Ex-offender


How Being a Social Enterprise Apprentice Changed Life of Ex-offender

A former criminal has recently graduated from Jamie Oliver’s apprentice program at Fifteen London. Andy Kabeya believes he would be back in prison if he hadn’t enrolled in Fifteen’s scheme.




Jobs in the Social Sector

  Foundation Related Jobs
  Social Work Jobs
  Executive Director Jobs
  Program Director Jobs
  Fundraising & Development Jobs





More Federal Domestic Assistance Programs


Payments for Essential Air Services | Tribal Youth Program | Rehabilitation Mortgage Insurance | Communications Information and Assistance and Investigation of Complaints | Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2019 Copyright Michael Saunders